[{"id":"d69d9e8b-481b-4b6a-a241-66952601f3da","acronym":"RITZ","url":"https://clinicaltrials.gov/study/NCT05735834","created_at":"2023-02-21T16:01:53.200Z","updated_at":"2025-02-25T14:03:19.754Z","phase":"Phase 3","brief_title":"Comparison Between Rituximab Plus Zanubrutinib Versus Rituximab Monotherapy in Untreated SMZL Patients","source_id_and_acronym":"NCT05735834 - RITZ","lead_sponsor":"International Extranodal Lymphoma Study Group (IELSG)","biomarkers":" MYD88 • CCND1 • BCL6 • IL2RA • MME • ITGAE • ISG20","pipe":" | ","alterations":" IL2RA expression","tags":["MYD88 • CCND1 • BCL6 • IL2RA • MME • ITGAE • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IL2RA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Brukinsa (zanubrutinib) • Truxima (rituximab-abbs)"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 05/21/2024","start_date":" 05/21/2024","primary_txt":" Primary completion: 05/01/2029","primary_completion_date":" 05/01/2029","study_txt":" Completion: 05/01/2029","study_completion_date":" 05/01/2029","last_update_posted":"2025-02-19"},{"id":"5a303c76-55bb-4d25-9d62-95ca56707b39","acronym":"","url":"https://clinicaltrials.gov/study/NCT05699603","created_at":"2023-01-26T15:02:41.396Z","updated_at":"2024-07-02T16:35:03.743Z","phase":"Phase 2","brief_title":"Testing the Efficacy of Topical Calcipotriene Plus 5-Fluorouracil Combination to Activate the Immune System Against Precancerous Skin Lesions in Organ Transplant Recipients","source_id_and_acronym":"NCT05699603","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4 • ITGAE • TSLP","pipe":"","alterations":" ","tags":["CD4 • ITGAE • TSLP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fluorouracil topical"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 08/18/2024","start_date":" 08/18/2024","primary_txt":" Primary completion: 02/01/2027","primary_completion_date":" 02/01/2027","study_txt":" Completion: 02/01/2029","study_completion_date":" 02/01/2029","last_update_posted":"2024-05-14"},{"id":"a2dce45d-64bf-4128-876e-4a25b3b1a037","acronym":"","url":"https://clinicaltrials.gov/study/NCT01059786","created_at":"2021-01-18T04:10:26.425Z","updated_at":"2024-07-02T16:35:06.574Z","phase":"Phase 2","brief_title":"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia","source_id_and_acronym":"NCT01059786","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD20 • CD22 • IL2RA • ITGAE • ITGAX • ISG20","pipe":" | ","alterations":" CD20 positive","tags":["CD20 • CD22 • IL2RA • ITGAE • ITGAX • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • bendamustine • pentostatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 07/01/2010","start_date":" 07/01/2010","primary_txt":" Primary completion: 12/15/2022","primary_completion_date":" 12/15/2022","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2024-05-01"},{"id":"90515a21-3e57-41de-96be-20611fb49d4e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05065554","created_at":"2021-10-04T12:52:56.869Z","updated_at":"2025-02-25T15:00:05.879Z","phase":"Phase 2","brief_title":"ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy","source_id_and_acronym":"NCT05065554","lead_sponsor":"Shayna Sarosiek, MD","biomarkers":" CD20 • CD22 • IL2RA • CD5 • SDC1 • CD27 • MME • ITGAE • FCER2","pipe":"","alterations":" ","tags":["CD20 • CD22 • IL2RA • CD5 • SDC1 • CD27 • MME • ITGAE • FCER2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • Calquence (acalabrutinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 11/16/2021","start_date":" 11/16/2021","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 10/01/2028","study_completion_date":" 10/01/2028","last_update_posted":"2024-04-17"},{"id":"613e6d83-8a24-4773-9fa7-ac0078156fbe","acronym":"","url":"https://clinicaltrials.gov/study/NCT02131753","created_at":"2021-01-18T09:53:21.117Z","updated_at":"2024-07-02T16:35:48.422Z","phase":"Phase 2/3","brief_title":"Therapy Optimisation for the Treatment of Hairy Cell Leukemia","source_id_and_acronym":"NCT02131753","lead_sponsor":"University of Giessen","biomarkers":" CD19 • IL2RA • ITGAE • ISG20","pipe":"","alterations":" ","tags":["CD19 • IL2RA • ITGAE • ISG20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cladribine"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 05/01/2004","start_date":" 05/01/2004","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2023-05-10"},{"id":"5a2242ee-9189-4e75-8e69-0041e4514703","acronym":"Apollo","url":"https://clinicaltrials.gov/study/NCT05761132","created_at":"2023-03-09T15:01:27.449Z","updated_at":"2024-07-02T16:35:53.672Z","phase":"Phase 2","brief_title":"Neo-adjuvant Pembrolizumab in Vulvar Squamous Cell Carcinoma: a Clinical Proof-of-concept Study","source_id_and_acronym":"NCT05761132 - Apollo","lead_sponsor":"Leiden University Medical Center","biomarkers":" PD-L1 • PD-1 • CD4 • ITGAE • ENTPD1","pipe":" | ","alterations":" ENTPD1 expression","tags":["PD-L1 • PD-1 • CD4 • ITGAE • ENTPD1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ENTPD1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 04/01/2023","start_date":" 04/01/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2023-03-09"},{"id":"4e579bc4-0edb-4785-98c5-7919d0eac97b","acronym":"DOMEC","url":"https://clinicaltrials.gov/study/NCT03951415","created_at":"2021-04-01T23:53:05.952Z","updated_at":"2025-02-25T15:08:32.159Z","phase":"Phase 2","brief_title":"Durvalumab and Olaparib in Metastatic or Recurrent Endometrial Cancer","source_id_and_acronym":"NCT03951415 - DOMEC","lead_sponsor":"Leiden University Medical Center","biomarkers":" PD-1 • LAG3 • CTLA4 • CD163 • CD14 • CD68 • ITGAE • KLRB1 • KLRC1","pipe":"","alterations":" ","tags":["PD-1 • LAG3 • CTLA4 • CD163 • CD14 • CD68 • ITGAE • KLRB1 • KLRC1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Imfinzi (durvalumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 07/08/2019","start_date":" 07/08/2019","primary_txt":" Primary completion: 08/01/2021","primary_completion_date":" 08/01/2021","study_txt":" Completion: 08/01/2021","study_completion_date":" 08/01/2021","last_update_posted":"2021-04-01"},{"id":"46a60911-95ea-49e1-9116-ac29702f16ef","acronym":"BioUV2017","url":"https://clinicaltrials.gov/study/NCT03340155","created_at":"2021-01-18T16:29:55.696Z","updated_at":"2024-07-02T16:37:16.400Z","phase":"","brief_title":"Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases","source_id_and_acronym":"NCT03340155 - BioUV2017","lead_sponsor":"Medical University of Graz","biomarkers":" CD8 • IL2RA • CD163 • PTPRC • NCAM1 • CD68 • FOXP3 • ITGAE • ITGAX • ISG20","pipe":"","alterations":" ","tags":["CD8 • IL2RA • CD163 • PTPRC • NCAM1 • CD68 • FOXP3 • ITGAE • ITGAX • ISG20"],"overall_status":"Recruiting","enrollment":" Enrollment 240","initiation":"Initiation: 10/30/2017","start_date":" 10/30/2017","primary_txt":" Primary completion: 10/01/2022","primary_completion_date":" 10/01/2022","study_txt":" Completion: 10/01/2022","study_completion_date":" 10/01/2022","last_update_posted":"2017-11-13"}]